Systemic Lupus Erythematosus (With and Without Nephritis)

Immunology
1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Allogene Therapeutics
Allogene TherapeuticsSOUTH SAN FRANCISCO, CA
1 program
1
ALLO-329Phase 11 trial
Active Trials
NCT07085104RecruitingEst. Oct 2032

Trial Timeline

Clinical trial activity over time

2025
2026
2027
2028
2029
2030
2031
Allogene TherapeuticsALLO-329

Clinical Trials (1)

A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

Start: Nov 2025Est. completion: Oct 2032
Phase 1Recruiting

Related Jobs in Immunology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials
1 companies competing in this space